Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021–June 2022

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2024-07-16 DOI:10.1111/irv.13339

Ryan Sandford, Ruchi Yadav, Emma K. Noble, Kelsey Sumner, Devyani Joshi, Sara Y. Tartof, Karen J. Wernli, Emily T. Martin, Manjusha Gaglani, Richard K. Zimmerman, H. Keipp Talbot, Carlos G. Grijalva, Edward A. Belongia, Christina Carlson, Melissa Coughlin, Brendan Flannery, Brad Pearce, Eric Rogier

{"title":"Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021–June 2022","authors":"Ryan Sandford, Ruchi Yadav, Emma K. Noble, Kelsey Sumner, Devyani Joshi, Sara Y. Tartof, Karen J. Wernli, Emily T. Martin, Manjusha Gaglani, Richard K. Zimmerman, H. Keipp Talbot, Carlos G. Grijalva, Edward A. Belongia, Christina Carlson, Melissa Coughlin, Brendan Flannery, Brad Pearce, Eric Rogier","doi":"10.1111/irv.13339","DOIUrl":null,"url":null,"abstract":"<p>We describe humoral immune responses in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS-CoV-2 infection.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13339","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13339","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

We describe humoral immune responses in 105 ambulatory patients with laboratory-confirmed SARS-CoV-2 Omicron variant infection. In dried blood spot (DBS) collected within 5 days of illness onset and during convalescence, we measured binding antibody (bAb) against ancestral spike protein receptor binding domain (RBD) and nucleocapsid (N) protein using a commercial multiplex bead assay. Geometric mean bAb concentrations against RBD increased by a factor of 2.5 from 1258 to 3189 units/mL and by a factor of 47 against N protein from 5.5 to 259 units/mL between acute illness and convalescence; lower concentrations were associated with greater geometric mean ratios. Paired DBS specimens may be used to evaluate humoral response to SARS-CoV-2 infection.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2021 年 12 月至 2022 年 6 月，对无症状感染 SARS-CoV-2 Omicron 变异病毒的抗体反应。

我们描述了 105 名经实验室确诊感染 SARS-CoV-2 Omicron 变体的非卧床患者的体液免疫反应。在发病后 5 天内和康复期间采集的干血斑（DBS）中，我们使用一种商用多聚酶珠测定法测定了针对祖先尖峰蛋白受体结合域（RBD）和核壳蛋白（N）的结合抗体（bAb）。在急性期和恢复期之间，针对 RBD 的几何平均 bAb 浓度增加了 2.5 倍，从 1258 个单位/毫升增至 3189 个单位/毫升；针对 N 蛋白的几何平均 bAb 浓度增加了 47 倍，从 5.5 个单位/毫升增至 259 个单位/毫升；浓度越低，几何平均比率越大。配对的 DBS 标本可用于评估对 SARS-CoV-2 感染的体液反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.